OncoMatch/Clinical Trials/NCT04375384
Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer
Is NCT04375384 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Cetuximab for head and neck squamous cell carcinoma.
Treatment: Cetuximab — This is a Phase II treatment, non-randomized, open label clinical trial to study the efficacy of the Cetuximab when administered as single agent in recurrent/ metastatic head and neck squamous cell carcinoma after the failure or intolerance of immuno-oncology or immuno-oncology combined with chemotherapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Metastatic disease required
Metastatic Head-and-neck Squamous-cell Carcinoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: anti-PD-1 therapy
previous treatment with immunotherapy with PD-1 inhibitor alone or in combination with chemotherapy
Cannot have received: EGFR-targeted therapy (cetuximab)
Exception: allowed if >5 years ago
Prior treatment with Cetuximab or prior therapy that specifically and directly targets the epidermal growth factor receptor (EGFR) pathway in the last five (5) years.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Wake Forest Baptist Comprehensive Cancer Center · Winston-Salem, North Carolina
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify